Trinity Biotech plc (TRIB) Stock Price

TRIBStock

$8.03−73.76%52W

Market Cap$6.53M

P/E—

PEG Ratio0.30

Div yield—

Beta1.04

TRIB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-72.47%

Price vs S&P 500 (4W)10.58%

PEG Ratio0.30

VGM Score42.34

Book Value / Share (Quarterly)$0.20

P/TBV (Annual)281.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-11.20%

Cash Flow / Share (Quarterly)$-0.03

Price vs S&P 500 (YTD)-78.04%

Gross Margin (TTM)32.88%

Net Profit Margin (TTM)-72.78%

EPS (TTM)$-0.10

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-0.10

Revenue Growth (5Y)-15.56%

EPS (Annual)$-0.10

ROI (Annual)-27.05%

Gross Margin (Annual)38.57%

Net Profit Margin (5Y Avg)-48.75%

Cash / Share (Quarterly)$0.01

Revenue Growth QoQ (YoY)-30.18%

ROA (Last FY)-35.54%

Revenue Growth TTM (YoY)-16.57%

EBITD / Share (TTM)$-0.04

ROE (5Y Avg)-161.55%

Operating Margin (TTM)-30.74%

Cash Flow / Share (Annual)$-0.03

P/B Ratio0.77x

P/B Ratio (Quarterly)3.37x

Net Income / Employee (Annual)$-93,200

EV / Revenue (TTM)2.69x

Net Interest Coverage (TTM)-0.74x

ROA (TTM)-36.62%

EV / EBITDA (TTM)1815.22x

EPS Incl Extra (Annual)$-0.10

Current Ratio (Annual)0.25x

Quick Ratio (Quarterly)0.12x

3-Month Avg Trading Volume0.05M

52-Week Price Return-73.76%

Revenue / Employee (TTM)$128,100

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)0.12x

Asset Turnover (Annual)0.42x

52-Week High$52.50

Operating Margin (5Y Avg)-28.83%

EPS Excl Extra (Annual)$-0.10

CapEx CAGR (5Y)-9.41%

Tangible BV CAGR (5Y)-67.56%

26-Week Price Return-62.56%

Quick Ratio (Annual)0.11x

13-Week Price Return-20.26%

Total Debt / Equity (Annual)21.68x

Current Ratio (Quarterly)0.25x

Enterprise Value$137.96M

Revenue / Share Growth (5Y)-37.33%

Asset Turnover (TTM)0.50x

Book Value / Share Growth (5Y)-52.97%

Revenue / Employee (Annual)$109,200

Inventory Turnover (Annual)1.41x

Pretax Margin (Annual)-84.91%

Cash / Share (Annual)$0.01

3-Month Return Std Dev130.45%

Gross Margin (5Y Avg)35.29%

Net Income / Employee (TTM)$-93,200

ROE (Last FY)-613.49%

Net Interest Coverage (Annual)-0.74x

EPS Basic Excl Extra (Annual)$-0.10

P/FCF (TTM)8.31x

Receivables Turnover (TTM)3.73x

Total Debt / Equity (Quarterly)8.73x

EPS Incl Extra (TTM)$-0.10

Receivables Turnover (Annual)3.72x

ROI (TTM)-24.46%

P/S Ratio (TTM)0.10x

Pretax Margin (5Y Avg)-54.44%

Revenue / Share (Annual)$0.12

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)-89.29%

Year-to-Date Return-66.12%

5-Day Price Return22.41%

EPS Normalized (Annual)$-0.10

ROA (5Y Avg)-30.10%

Net Profit Margin (Annual)-85.36%

Month-to-Date Return24.88%

Cash Flow / Share (TTM)$-1.26

EBITD / Share (Annual)$-0.04

Operating Margin (Annual)-36.06%

LT Debt / Equity (Annual)17.40x

ROI (5Y Avg)-22.34%

LT Debt / Equity (Quarterly)8.70x

EPS Basic Excl Extra (TTM)$-0.10

P/TBV (Quarterly)281.74x

P/B Ratio (Annual)5.27x

Inventory Turnover (TTM)1.41x

Pretax Margin (TTM)-72.39%

Book Value / Share (Annual)$0.25

Price vs S&P 500 (13W)-22.94%

Beta1.04x

P/FCF (Annual)1.12x

Revenue / Share (TTM)$0.14

ROE (TTM)-166.14%

52-Week Low$5.01

vGradeB

gGradeD

mGradeC

vgmGradeC

TRIB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2025	Jul 1, 2025	—	-$14.40	—
Q4 2024	May 15, 2025	-$9.00	-$26.35	-192.75%(-$17.35)
Q3 2024	Nov 15, 2024	-$16.20	-$12.77	+21.15%(+$3.43)
Q2 2024	Aug 14, 2024	-$19.50	-$14.00	+28.20%(+$5.50)

TRIB Analyst Recommendations

Oct 2022

Nov 2022

Dec 2022

Jan 2023

4.29

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About Trinity Biotech plc

Trinity Biotech develops and manufactures clinical diagnostic products for laboratory and point-of-care testing, focusing on detection of autoimmune, infectious, and sexually transmitted diseases, as well as diabetes and organ-specific disorders. The company also supplies raw materials to the global life sciences and research industries. The Americas segment accounts for the majority of revenue.